Hormone therapy before surgery for extensive DCIS
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether taking hormone medicine before surgery can change the surgical plan and outcomes for people with extensive ductal carcinoma in situ (DCIS). It is for estrogen-receptor positive DCIS and aims to see how this “neoadjuvant” approach affects treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 40 years old
- Have DCIS (a non-invasive breast condition), not invasive cancer
- Your DCIS must be estrogen-receptor positive; progesterone status doesn’t matter
- Your planned surgery is a mastectomy (removal of the breast)
- Your DCIS must be seen on a breast MRI, and an MRI “clip sequence” is used
- You should be able to attend follow-up visits and complete the study; also able to use effective birth control if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether active surveillance (close monitoring) is a good option for certain patients with hormone-positive DCIS who have positive surgical margins after initial surgery. You would receive no immediate additional treatment—just regular imaging and check-ups.
This trial studies treatments given before surgery for invasive breast cancer, aiming to shrink the tumor so surgery can be done more effectively. It may help some people need breast-conserving surgery or improve the chance of complete cancer removal.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
This trial tests whether taking endocrine therapy (medication that blocks estrogen) can help some women with very early breast changes (like DCIS or ADH) avoid surgery. It is for women whose cells are strongly estrogen receptor positive and not HER2 positive.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.